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RESUMO
Introdução: O papel dos eosinófilos na carcinogénese colorretal tem sido discutido em várias publicações científicas. O objetivo 
deste estudo foi o de rever o valor dos eosinófilos tecidulares no prognóstico do cancro colorretal, enfatizando a sua identificação, 
mensuração e associação com as características clinicopatológicas da doença.
Material e Métodos: Utilizámos os motores de busca PubMed e Web of Science para pesquisar estudos que associassem os 
eosinófilos tecidulares com o prognóstico do cancro colorretal.
Resultados: Selecionámos 15 estudos para a nossa revisão. Maioritariamente, a análise do infiltrado foi realizada através da 
coloração de hematoxilina-eosina, com criação de scores. A maioria dos trabalhos descreveu a eosinofilia tecidular como um fator 
de prognóstico favorável no cancro colorretal e estabeleceu uma associação inversa entre ela e o comportamento metastático dos 
tumores. A associação com outros fatores de prognóstico foi por vezes abordada, com resultados inconsistentes. A eosinofilia tecidular 
diminuiu na progressão adenoma-carcinoma.
Discussão: Vários mecanismos têm sido propostos para explicar a quimiotaxia de eosinófilos para os tecidos tumorais e a sua 
interação com as células neoplásicas, sugerindo o envolvimento dos eosinófilos na progressão do cancro colorretal. Apesar de não 
existir um sistema de avaliação validado, a eosinofilia tecidular associada a tumores pode constituir um parâmetro histopatológico de 
prognóstico no cancro colorretal.
Conclusão: As evidências disponíveis associam a presença de eosinófilos no microambiente do cancro colorretal com a modulação 
da sua progressão. O impacto clínico deste achado deve ser estudado no futuro.
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ABSTRACT
Introduction: Amongst the inflammatory cells implicated in the immune surveillance of colorectal cancer, a growing body of evidence 
suggests a role for eosinophils in carcinogenesis. We aimed to review the value of tumour-associated tissue eosinophilia (TATE) in the 
prognosis of colorectal cancer emphasizing the identification and measurement of tissue-infiltrating eosinophils and their association 
with the clinicopathological features of the disease.
Material and Methods: We used PubMed and Web of Science search engines to retrieve studies that looked at the association 
between tissue eosinophils and colorectal cancer prognosis.
Results: We selected 15 studies for our review. In the majority of the studies, eosinophils were identified in hematoxylin-eosin stained 
sections and scores were generated for analysis. Most of the studies pointed to tumour-associated tissue eosinophilia as a favourable 
prognostic marker in colorectal cancer and found an inverse association between eosinophil count and the metastatic potential of 
these neoplasms. The association between tumour-associated tissue eosinophilia and established prognostic markers of colorectal 
cancer was assessed in some studies, with inconsistent results. Additionally, tumour-associated tissue eosinophilia decreased with the 
adenoma-carcinoma progression of colorectal lesions.
Discussion: Several mechanisms have been proposed regarding eosinophil chemoatraction to tumour tissues and eosinophil-cancer 
cell cross-talk, suggesting that eosinophils are actively involved in colorectal cancer progression. Although a scoring system is still 
lacking, tumour-associated tissue eosinophilia meets the criteria of a convenient histopathological prognosticator in colorectal cancer. 
Conclusion: Collectively, current evidence associates the presence of eosinophils in the colorectal cancer microenvironment with the 
modulation of tumour progression. The clinical impact of this finding deserves future research.
Keywords: Colorectal Neoplasms; Eosinophils; Precancerous Conditions; Prognosis
INTRODUCTION
 Colorectal cancer (CRC) is a leading neoplasia and 
a major cause of cancer mortality worldwide,1 whose 
incidence has increased in recent years. Thus, great efforts 
have been developed to deepen our understanding of the 
disease. The identification of new prognostic factors and 
predictors of disease progression is of particular interest, 
since therapeutic options offered to CRC patients may 
depend on them. 
 The tumour, node, metastasis (TNM) stage system of 
the American Joint Committee on Cancer (AJCC) is the 
strongest prognosticator and the major determinant for 
management of patients diagnosed with CRC.2 However, for 
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intermediate stages of the disease, the TNM classification 
loses strength since for some patients with stage II CRC, 
complete surgical excision may be curative, but for other 
patients with the same stage, adjuvant therapies may be 
necessary.3 Therefore, additional risk assessment is of 
utmost importance in these patients.3
 Different histopathological prognostic markers have 
been assigned to CRC patients, namely histomorphological 
variants of CRC, tumour differentiation, lymphatic and 
venous invasion, perineural invasion, tumour budding, 
tumour necrosis and inflammatory response.4 Importantly, 
novel prognostic markers must not only be accurate, but also 
easily accessible on hematoxylin-eosin stained specimens 
and broadly applicable.4 In this context, correlates of 
inflammatory responses may prove of interest.
 Several authors have reviewed the value of local 
inflammatory reaction in CRC prognosis. Cells of both 
the innate and the adaptive immune systems are found 
in infiltrating CRCs, with a dual effect on the stimulation 
and inhibition of CRC growth.5 Overall tissue inflammatory 
infiltration has been considered as a favourable prognostic 
marker.4,6 Amongst the specific types of inflammatory cells 
implicated in CRC prognosis, T lymphocytes have been 
related both to positive and negative outcomes, depending 
on the subset considered.5,6 Importantly, it is well established 
that CD3+ and CD8+ T cells infiltrates are related to good 
prognosis.5-7 Concerning macrophages, the results are 
also contradictory since M1 and M2 macrophages are 
associated with tumour growth inhibition and stimulation, 
respectively.5,8 However, CD68+ macrophages have been 
linked to a favourable outcome.4,6 Neutrophils, mast cells 
and dendritic cells have been also implicated in CRC 
prognosis to a lesser extent.5,6 
 Eosinophilic infiltration of tumour tissues, also called 
tumour-associated tissue eosinophilia (TATE), has been 
referred as an easily recognizable histological parameter, 
related with survival and recurrence of CRC.4 Several studies 
reported TATE in CRC as an independent prognostic factor. 
However, the role of eosinophils in colorectal carcinogenesis 
is still not fully understood. Therefore, a review of the 
literature in this area of study may have a great impact on the 
understanding of previously published data. Furthermore, it 
will certainly raise awareness as to the importance of these 
immune cells in the context of future research studies. In 
the present work, we aimed to review the value of TATE 
in the prognosis of CRC, highlighting the identification 
and measurement of tissue-infiltrating eosinophils and the 
association of TATE with clinicopathological features and 
prognostic outcomes in patients diagnosed with CRC.
MATERIAL AND METHODS
 We performed a literature search using PubMed and 
Web of Science, for articles published until June 27, 2017. 
Regarding the search strategy and inclusion criteria for 
the main purposes of our review, the search terms were 
‘colorectal cancer AND eosinophils’. Only articles published 
in English were considered. No limits were applied 
concerning the year of publication. Review articles and 
unavailable abstracts were excluded. After scanning the 
titles and abstracts of the retrieved studies, we selected the 
full text of 15 original research articles in accordance with the 
objectives established and all articles were included in our 
review.9-23 Data from the included studies were independently 
extracted from each study and comprised: author; year of 
publication; sample size; participants’ characteristics (mean 
age and gender proportion); follow-up assessment; tumour 
classification, stage and clinicopathological features; TATE 
characterization (i.e. staining, count and location); and major 
findings. In order to enable a better understanding of our 
work, we performed a broad search of the literature on the 
biology of eosinophils and their role in cancer, as well as on 
CRC up-to-date information, prognosis, microenvironment 
and inflammation. We included the most significant studies 
in the final reference list.
RESULTS
Baseline characteristics of the selected studies
 We incorporated 15 original research articles in our 
review, published between 1983 and 2016.9-23 Twelve 
studies associated TATE with survival and/or metastatic 
behaviour of CRC9,11,12,14-16,18-23 and three studies associated 
TATE with malignant progression of colorectal lesions.10,13,17 
The first set of studies evaluated 2523 CRCs.9,11,12,14-16,18-23 
The mean age of the participants was recorded in seven 
studies and ranged between 62.1 and 73 years.9,11,14,16,21-23 
Nine studies detailed gender proportion, totalling 835 males 
and 1136 females.9,11,12,14,16,18,21-23 Nine studies specified the 
CRC staging approach: TNM was used in four studies9,11,12,15 
and Dukes staging was performed in five studies.14,16,18,20,23 
The median follow-up interval was recorded in five studies 
and ranged from 35.4 to 105 months.9,11,12,15,18 In one study, 
the average time that patients were in the study was 73 
months.20 In other studies, the follow-up period was 60 
months or longer.14,16 Luebbers et al assessed survival 
data for periods between one and 47 months.21 Pretlow et 
al recorded survival data for a period of 11 months for all 
patients, although for the majority of the patients included 
in their study, the follow-up period was18 months.23 The 
second set of three studies comprised a total of 986 
colorectal benign and malignant lesions.10,13,17 In these 
studies, no information was recorded concerning the mean 
age of participants and gender proportion.10,13,17 A summary 
of the selected studies is presented in Table 1.
TATE characterization
 In seven of the studies herein included, eosinophils 
were identified in hematoxylin-eosin stained 
sections.10-13,16-18 In one study, eosinophils were assessed 
by immunohistochemistry for eosinophil peroxidase 
(clone 144B, homebrew from Dr. James Lee, Mayo Clinic, 
Arizona).9 In another study, the authors included both 
methods for eosinophil staining, applying the antibody 
EG-2 (Anti-Human ECP/EPX, Pharmacia Upjohn, Uppsala, 
Sweden) in immunohistochemistry technique.15 In three 
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articles, eosinophils were identified by hematoxylin, eosin 
Y and azure II staining procedure.19,21,22 Also, in two articles 
Giemsa staining was used for eosinophil recognition.20,23 In 
one study, the staining procedure was not clearly reported, 
but presumably hematoxylin-eosin staining was used.14
 Regarding eosinophil counts, most of the studies 
established scores based on the number of eosinophils in 
a particular area or the percentage of eosinophils relative 
to total stromal inflammatory cells (seven and two studies, 
respectively).9,11-13,15-18,20 In five articles, scores were not 
applied.10,19,21-23 In one study the authors considered three 
categories for analysis.14
 The location of eosinophil counts within the lesions was 
reported in 13 studies.9-15,17-22 In the study performed by 
Prizment et al, eosinophils were counted in the epithelial 
and stromal compartments.9 Cho et al performed cell counts 
in the mucosa and submucosa, near the neoplastic lesion.10 
In three studies, intratumoural and peritumoural eosinophils 
were assessed.11,13,15 Richards et al, Nespoli et al and Nielsen 
et al evaluated only peritumoural eosinophils.12,14,18 In other 
three studies, the authors counted eosinophils in sections 
remote from the margin and contiguous to the margin, 
defined as “one cm from the border of tumour with uninvolved 
mucosa” and “the border itself”, respectively.19,21,22 In one 
study, the eosinophil count was performed in the stroma 
of the lesions; in invasive carcinoma cases, the authors 
assessed the transitional zone in particular (“the area 
between normal tissue and tumour”).17 In another article, 
the authors presented eosinophil counts in the “interface 
of the tumour and underlying tissues at the site of deepest 
penetration”.20
 A summary of TATE characterization described in the 
selected studies is presented in Table 2.
TATE as a favourable prognostic marker in CRC 
 In nine studies included in our review, survival analyses 
were performed in relation to TATE.9,11,12,14-16,18,20,23 Table 3 
highlights the association between TATE and prognostic 
outcomes within each study.
 Briefly, TATE was associated with improved overall 
and/or CRC-specific survival in seven studies.9,11,15,16,18,20,23 
Further, TATE was inversely associated with all-cause and 
CRC-specific death in the study of Prizment et al.9 TATE 
could also predict progression-free survival in one study11 
and relapse-free survival in another study.16 Importantly, five 
studies pointed TATE as an independent prognostic factor in 
Table 1 – Summary of the selected studies
First author, year of 
publication
Sample 
size
Patients Median
follow-up
(months)
Tissue samples
Mean age of 
participants (years)
Gender proportion 
(male/female) Tumour classification
Tumour 
staging
Tumour 
stages
Prizment, 20169 441 73 0/441 104.4 Colorectal cancer TNM NR
Cho, 201610 50 NR NR NA Tubular adenoma (low 
and high grade dysplasia) 
Adenocarcinoma
NR NR
Harbaum, 201511 381 68.5 166/215 45 Adenocarcinoma
Others
TNM I-IV
Richards, 201212 130 68% of patients ≥ 65 68/62 105 Colorectal cancer TNM I-III
Kiziltaᶊ, 200813 448 NR NR NA Hyperplastic polyp
Serrated adenoma
Tubular adenoma
Tubulovillous adenoma 
Villous adenoma
Adenocarcinoma
NR NR
Nespoli, 200414 192 65.6 and 62.1* 105/87 60† Colorectal adenocarcinoma Dukes B and C
Nagtegaal, 200115 160 NR NR 35.4 Rectal adenocarcinoma TNM I-IV 
Fernández-Aceñero, 
200016
126 67.4 70/56 60 
(minimum)
Colorectal carcinoma, 
excluding signet ring and 
mucinous variants
Dukes A-C
Moezzi, 200017 488 NR NR NA Hyperplastic polyp
Tubular adenoma
Tubulovillous adenoma
Villous adenoma
Intramucosal carcinoma
Invasive adenocarcinoma
NR NR
Nielsen, 199918 584 70 (median) 344/240 61 Colorectal cancer Dukes A-D
McGinnis, 198919 61 NR NR NA Colonic carcinoma NR NR
Fisher, 198920 331 NR NR 73‡ Rectal carcinoma Dukes A-D
Luebbers, 198521 24 62.7 19/5 1 to 47§ Colorectal carcinoma NR NR
Pretlow, 198422 26 63.9 21/5 NA Colorectal carcinoma NR NR
Pretlow, 198323 67 65.3 42/25 11 and 18§ Colorectal carcinoma Dukes B and C
NR: not reported; NA: not applicable
* with and without postoperative infection, respectively; † follow-up period after surgery; ‡ average time on study; § range of follow-up periods
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CRC.9,11,15,16,18 Also significant, in four studies, the prognostic 
value of TATE was maintained in intermediate stages of 
the disease - TNM stages II and III or Dukes stages B and 
C.9,11,18,23 Two studies stated a lack of association between 
eosinophil count and cancer-specific or overall survival in 
univariate analysis.12,14
Association between TATE and metastatic behaviour of 
CRC 
 Nagtegaal et al described a significant association 
between high scores of eosinophils and lower rates of distant 
metastases (p = 0.03).15 Additionally, an inverse relationship 
was observed between peritumoural eosinophils and local 
recurrence and distant metastases (p = 0.007 and p = 0.009, 
respectively).15 Four other studies described significantly 
higher concentrations of eosinophils in tumours without 
metastases as compared to metastatic ones (p < 0.05).19,21-
23 In one of those studies, the proportion of tumours with less 
than 30 eosinophils / mm2 with metastases was significantly 
higher than the proportion of tumours with more than 30 
eosinophils / mm2 with metastases.23 Later on, the same 
group suggested a threshold lower than 30 eosinophils 
/ mm2.22 In another study of the same group, cut-offs 
predictive of absence of metastases were proposed, namely 
20 eosinophils / mm2 and 25 eosinophils / mm2, respectively 
depending on whether sections remote or contiguous to the 
margin of the tumour were considered.19
Association between TATE and established prognostic 
factors of CRC
 Several items related to patients and tumour 
characteristics were analysed in association with TATE in the 
herein included studies. In this section, we summarize the 
association between TATE and the established prognostic 
factors of CRC, namely: stage, grade (differentiation), 
lymphatic, venous and perineural invasion, tumour budding 
Table 2 – Summary of methods described in the selected studies to achieve TATE characterization
First author, year of 
publication
TATE characterization
Staining Count Location
Prizment, 20169 IHC 3 to 4 scores based on the No. 
of EØ / 0.28 mm2
Epithelium and stroma
Cho, 201610 HE No. of EØ in 3 hotspots 
evaluated at HPF
Mucosa and submucosa near 
neoplastic lesion
Harbaum, 201511 HE 4 scores based on the No. of EØ 
/ 0.24 mm2
Intratumoural and peritumoural
Richards, 201212 HE 2 groups based on the median 
EØ count / 0.018 mm2
Peritumoural
Kiziltaᶊ, 200813 HE 3 scores based on the 
percentage of EØ relative to total 
stromal inflammatory cells
Intratumoural and peritumoural 
Nespoli, 200414 NR (presumably, HE) 3 categories: absent, moderate 
or conspicuous
Peritumoural
Nagtegaal, 200115 HE
IHC 
3 scores based on the No. of EØ 
/ 2.1 mm2
Intratumoural and peritumoural
Fernández-Aceñero, 
200016
HE 2 or 4 groups based on the No. 
of EØ / HPF
NR
Moezzi, 200017 HE 3 scores based on the 
percentage of EØ relative to total 
stromal inflammatory cells
Stroma
Nielsen, 199918 HE 4 groups based on the No. of EØ 
/ 0.17 mm2
Peritumoural
McGinnis, 198919 Hematoxylin, eosin Y and azure 
II
No. of EØ / mm2 Sections remote from the margin
Sections contiguous to the 
margin
Fisher, 198920 Giemsa 3 scores based on the No. of EØ 
in 30 fields (x1000)
Interface of the tumour and 
underlying tissues at the site of 
deepest penetration
Luebbers, 198521 Hematoxylin, eosin Y and azure 
II
No. of EØ / mm2 Sections remote from the margin
Sections contiguous to the 
margin
Pretlow, 198422 Hematoxylin, eosin Y and azure 
II
No. of EØ / mm2 Sections remote from the margin
Sections contiguous to the 
margin
Pretlow, 198323 Giemsa No. of EØ / mm2 NR
TATE: tumour associated tissue eosinophilia; IHC: immunohistochemistry; No(s).: number(s); EØ: eosinophil(s); HE: hematoxylin-eosin; HPF: high power field; NR: not reported 
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and inflammation.4
 Higher eosinophil counts were significantly associated 
with lower CRC stage in four studies (p ≤ 0.04).9,11,15,20 In one 
study, the aforementioned association was not observed.16
 In two studies, TATE was associated with better tumour 
differentiation (p ≤ 0.05).11,20 However, these data were not 
corroborated in four other studies.9,15,16,22
 Increasing inflammatory reaction was positively 
associated with TATE in two studies (p ≤ 0.001).11,12 TATE 
was significantly correlated with several inflammatory cell 
types in different studies, namely CD8+, CD3+, CD4+, 
neutrophils, macrophages and mast cells.9,15 However, in 
three studies, no association was found between TATE and 
mast cell counts.18,20,23 The concentration of plasma cells 
was significantly related to the concentration of eosinophils 
in one study.19
 In one study, a higher eosinophil count was significantly 
associated with the absence of lymphatic and venous 
invasion and tumour budding (p ≤ 0.02).11 However, 
Fernández-Aceñero et al did not find an association 
between TATE and vascular or neural invasion.16
TATE in adenoma-carcinoma progression of colorectal 
lesions
 As stated before, three studies included in our review 
addressed the intensity of TATE in different colonic 
lesions, including hyperplastic polyps, adenomas and 
adenocarcinomas (Table 1).10,13,17 Table 4 summarizes the 
results of these studies.
 It was observed that the number of eosinophils 
significantly decreased throughout adenoma-carcinoma 
progression.10,13,17 The intensity of TATE in hyperplastic 
polyps was significantly lower than in adenomatous 
lesions13,17 and adenocarcinomas.13 In the study of Kiziltaᶊ 
et al, there was no significant difference in TATE intensity 
between low- and high grade dysplasia,13 in line with the 
results of Cho et al.10 Still, in both studies, the intensity 
of TATE was higher in high grade dysplasia compared to 
adenocarcinomas.10,13 Additionally, Moezzi et al described 
a higher TATE in intramucosal carcinoma compared to 
invasive carcinoma.17 Kiziltaᶊ et al further included serrated 
adenomas in their series and found that TATE was lower in 
the hyperplastic polyps and higher in adenomatous polyps 
compared to those lesions (p < 0.001).13
DISCUSSION
 Tumour microenvironment refers to the malignant and 
tumour-associated stromal and immune cells, as well as 
the cross-talk between them.24 The immune system plays 
a dual action both in cancer promotion and prevention.25 
Considering the critical role of the immune system in the 
recognition and elimination of transformed cells - cancer 
immunosurveillance - new insights have emerged regarding 
the prognostic role of immune infiltrates in tumour tissues.25 
In this context, TATE has been widely studied, as previously 
revised.4,6,26-31 In this study, we aimed at reviewing the 
prognostic value of TATE in CRC. In contrast to previous 
reviews, which summarized this topic in the context of wider 
subjects,4,6,26,28,29,31 our review included a larger number of 
studies and provided more detailed information on TATE 
characterization and on the association between TATE and 
other clinicopathological features in CRC. Moreover, we 
reviewed the association of TATE and adenoma-carcinoma 
progression. Therefore, we accomplished a more exhaustive 
understanding of the published data.
 TATE has been associated with a favourable prognosis 
in several types of solid tumours, including CRC.4,6,26-29,31 Our 
analysis adds to this concept. Importantly, the prognostic 
value of TATE was maintained when TNM stages II and III 
of the disease were considered.9,11 These findings support 
that the evaluation of TATE in CRC specimens may be 
useful for individual prognosis and might be used in the 
selection of patients who benefit from aggressive therapies 
as previously suggested.4,16,18,29
 Despite the association found in different studies, the 
mechanisms by which eosinophils are recruited to the 
cancer niche and influence cancer prognosis remain unclear. 
However, current knowledge suggests that TATE plays an 
active and protective role in CRC progression rather than 
being an occasional finding. Understanding the molecular 
mechanisms involved in the cross-talk between eosinophils 
and CRC cells would certainly contribute to improve the 
existing knowledge of the immunogenic characteristics of the 
disease and may have a major impact in the development 
of novel therapeutic targets.6,9,11,26,28,29,31-35 
 In the case of CRC, eosinophil recruitment, activation 
and survival was suggested to be dependent on local 
production of IL-5 by tissue resident eosinophils36 and 
active damage associated molecular pattern (DAMP) 
molecules, namely high mobility group box 1 (HMGB1), in 
the context of tumour cell necrosis.32 Surprising findings 
have been achieved on the role of eotaxins in eosinophil 
chemoatraction to CRCs, since low numbers of tissue 
eosinophils are found both in primary CRCs10,37 and liver 
metastases,37 albeit not always associated with low levels of 
tissue eotaxins.37,38 The contribution of neoplastic epithelial 
cells for the secretion of eotaxins appears to be residual.10,39 
Briefly, three mechanisms may explain the lower number 
of eosinophils in CRC tissues despite the often high levels 
of tissue eotaxins: the eosinophil chemoattractant role of 
eotaxins may be blocked in CRC37; lower levels of eotaxins 
in plasma may have impact in eosinophil traffic to the 
tissues38,39; or the differential eotaxins compartmentalization 
in CRC tissues influences eosinophil chemoatraction.10
 Following activation, several mechanisms for CRC 
control by eosinophils have been proposed. After attachment 
to carcinoma cells, eosinophils lose their IL-5 transcripts 
and undergo apoptosis, releasing their cytotoxic granules.36 
Eosinophil degranulation results in the release of major 
basic protein (MBP) and eosinophil peroxidase (EPO), which 
promote oxidation of cancer cell lysates, both directly and 
indirectly through neutrophils.32 Additionally, the cytotoxic 
effect of human eosinophils, inducing both apoptosis and 
necrosis, against intestinal carcinoma cell line Colo-205 was 
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assigned to eosinophil cationic protein, eosinophil derived 
neurotoxin (EDN), TNF-α, and granzyme A, depending on 
CD11a/CD18 for effector-target cell adhesion, and γδTCR/
CD3.40,41 The same group addressed IL-18 as a key mediator 
of eosinophils-Colo-205 cells contact, through CD11a 
and ICAM-1 adhesion molecules, contributing to the pro-
apoptotic action of eosinophils.33 Conversely, Taylor et al 
previously stated that CD11a was not involved in eosinophil 
binding to MCA-38 colon adenocarcinoma cells, but the 
authors used mouse eosinophils.42 Still, they attributed a 
direct cytotoxic effect of eosinophils against MCA-38 cells, 
demonstrating the role of protein tyrosine kinase and cyclic 
AMP in effector-target cell adhesion.42 Earlier, the local 
anti-tumour effect of IL-4 (secreted by engineered colon 26 
cells) was endorsed in part to eosinophils in an early stage, 
supporting an advantageous role of TATE in the defence 
against cancer.34 Recently, a protective role was also 
attributed to IL-18 in a mouse model of inflammatory colon 
cancer and inflammatory bowel disease (AOM/DSS mice).39 
The levels of IL-18 were likely related with TATE, rather than 
with epithelial cells secretion.39 IL-17E (IL-25) was found to 
increase TATE and inhibited tumour growth, through IL-5 
induction, in a human colon tumour xenograft model.35 
Thus, eosinophils may be engaged in the anti-tumour effect 
of IL-17E, and IL-17E was endorsed as a putative effective 
therapy in colon adenocarcinoma.35
 In addition to the aforementioned molecular 
mechanisms, the relation between eosinophils and other 
immune cells raises the hypotheses that eosinophils may 
also exert their action via other cells and vice-versa.9,15,19 
The interaction between eosinophils and other immune 
cells has been recognized.26-28,31,43 Interestingly, Nagtegaal 
et al proposed a model for protective immune responses 
in rectal cancer, in which T cells interact with nonspecific 
immune response (eosinophils, neutrophils, mast cells, 
macrophages and NK cells).15 All these cells have been 
implicated in CRC prognosis in different extents.4-6 Recently, 
Prizment et al suggested that eosinophils may act partially 
through cytotoxic T-cells in CRC.9 
 Despite the body of evidence placing eosinophils as 
cells with anti-tumoural activity, their therapeutic potential 
remains difficult to explore. This is greatly due to the lack 
of specific activity of eosinophils against tumoural cells.31 
Indeed, attracting eosinophils to the cancer niche and 
Table 3 – Association between TATE and prognostic outcomes
First author, year of publication Outcome measured Statistical methods Main findings
Prizment, 20169 - 5-year all-cause and CRC survival
- 5-year all-cause and CRC-specific death
- Total follow-up all-cause and CRC-specific death
- Kaplan-Meier plots and log-rank tests 
- Cox proportional hazards regression
- In univariate analysis, higher stromal EØ scores (versus lower stromal EØ scores) associated with better 5-year all-cause and CRC 
survival (p = 0.0006 and p = 0.001, respectively)
- In multivariate analysis, stromal EØ scores (highest versus lowest) inversely associated with risk for 5-year all-cause and CRC 
death (HR 0.61; 95% CI 0.36 - 1.02; p = 0.02 and HR 0.48; 95% CI 0.24 - 0.93; p = 0.01, respectively) as with total follow-up all-
cause and CRC-specific death (HR 0.72; 95% CI 0.48 - 1.08; p = 0.04 and HR 0.61; 95% CI 0.34 - 1.12; p = 0.04, respectively)
- The association was maintained with statistical significance when stages II and III were combined
- In both univariate and multivariate analyses, the highest score of epithelial EØ showed a trend to better outcomes, though without 
statistical significance
Harbaum, 201511 - Progression-free survival
- Cancer specific survival
- Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- Both peritumoural and intratumoural EØ associated significantly with progression-free and cancer specific survival (p < 0.001)
- Only peritumoural EØ independently associated with progression-free and cancer specific survival (HR 0.75; 95% CI 0.58 - 0.98; p 
= 0.04 and HR 0.7; 95% CI 0.53 - 0.93; p = 0.01, respectively)
- In patients with stage II CRC, the presence of peritumoural EØ (versus the absence of peritumoural EØ) independently associated 
with progression-free and cancer specific survival (HR 0.24; 95% CI 0.07 - 0.87; p = 0.03 and HR 0.25; 95% CI 0.06 - 1.02; p = 0.05, 
respectively)
Richards, 201212 - Cancer-specific survival - Kaplan-Meier
- Cox proportional hazards regression
- In univariate analysis, EØ count did not associate with cancer-specific survival (HR 1.72; 95% CI 0.89 - 3.35; p = 0.11)
Nespoli, 200414 - 5-year overall survival - Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- In univariate analysis, EØ infiltration did not associated with survival (p ≥ 0.3)
Nagtegaal, 200115 -Cumulative survival (2-year) 
- Local recurrence rate (2 year)
- Distant metastases rate (2year)
- Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- In univariate analysis, peritumoural EØ directly associated with cumulative survival (p = 0.0008) and inversely associated with local 
recurrence and distant metastases (p = 0.007 and 0.009, respectively)
- In multivariate analysis, peritumoural EØ showed independent prognostic value regarding cumulative survival, additional to TNM 
staging
Fernández-Aceñero, 200016 - Overall survival
- Relapse-free survival
- Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- Higher EØ counts independently associated with longer overall survival and relapse-free survival (p = 0.0005 and p = 0.0009, 
respectively)
Nielsen, 199918 - Overall survival - Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- EØ count significantly predicted a good overall survival (p < 0.0001), with a progressive effect of increasing counts on the survival 
improvement
- In univariate analysis, EØ count significantly associated with survival (HR 0.74; 95% CI 0.66 - 0.84; p < 0.0001)
- In multivariate analysis, EØ count independently associated with survival (HR 0.81; 95% CI 0.72 - 0.92; p = 0.001)
- EØ counts directly associated with survival in Dukes B and C stages (p = 0.03 and 0.002, respectively)
Fisher, 198920 - Overall survival - Life table plots
- Mantel-Cox statistic
- Overall survival was higher in patients whose tumours had 10 or more EØ
- After adjustment for Dukes’ stage or treatment, the No. of EØ had no prognostic value
Pretlow, 198323 - Survival at 18 months - Wilcoxon 2-sample test
- Fisher’s exact test
- Survival was significantly greater when more than 30 EØ / mm2 were counted (p = 0.028)
TATE: tumour associated tissue eosinophilia; CRC: colorectal cancer; EØ: eosinophil(s); HR: hazard ratio; CI: confidence interval; No(s).: number(s)
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activating them would most likely lead to detrimental 
damage of the remaining tissue, in addition to cancer cells.31 
Thus, important lines of research are opening for the future, 
mainly related to the development of strategies allowing 
eosinophils to specifically target cancer cells.31
 Concerning the association between TATE and other 
prognostic markers of CRC, the results of our review were 
inconsistent. The limited number of the included studies 
that associated TATE with overall inflammation or specific 
cell types and other clinicopathological prognosticators 
impaired a comprehensive analysis about this topic. The 
most reliable finding encompassed the association between 
higher eosinophil counts and lower CRC stage.9,11,15,20 The 
association between TATE and such a strong prognostic 
marker might validate the impact of TATE itself in CRC 
prognosis. Moreover, this finding suggests that TATE, 
Table 3 – Association between TATE and prognostic outcomes
First author, year of publication Outcome measured Statistical methods Main findings
Prizment, 20169 - 5-year all-cause and CRC survival
- 5-year all-cause and CRC-specific death
- Total follow-up all-cause and CRC-specific death
- Kaplan-Meier plots and log-rank tests 
- Cox proportional hazards regression
- In univariate analysis, higher stromal EØ scores (versus lower stromal EØ scores) associated with better 5-year all-cause and CRC 
survival (p = 0.0006 and p = 0.001, respectively)
- In multivariate analysis, stromal EØ scores (highest versus lowest) inversely associated with risk for 5-year all-cause and CRC 
death (HR 0.61; 95% CI 0.36 - 1.02; p = 0.02 and HR 0.48; 95% CI 0.24 - 0.93; p = 0.01, respectively) as with total follow-up all-
cause and CRC-specific death (HR 0.72; 95% CI 0.48 - 1.08; p = 0.04 and HR 0.61; 95% CI 0.34 - 1.12; p = 0.04, respectively)
- The association was maintained with statistical significance when stages II and III were combined
- In both univariate and multivariate analyses, the highest score of epithelial EØ showed a trend to better outcomes, though without 
statistical significance
Harbaum, 201511 - Progression-free survival
- Cancer specific survival
- Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- Both peritumoural and intratumoural EØ associated significantly with progression-free and cancer specific survival (p < 0.001)
- Only peritumoural EØ independently associated with progression-free and cancer specific survival (HR 0.75; 95% CI 0.58 - 0.98; p 
= 0.04 and HR 0.7; 95% CI 0.53 - 0.93; p = 0.01, respectively)
- In patients with stage II CRC, the presence of peritumoural EØ (versus the absence of peritumoural EØ) independently associated 
with progression-free and cancer specific survival (HR 0.24; 95% CI 0.07 - 0.87; p = 0.03 and HR 0.25; 95% CI 0.06 - 1.02; p = 0.05, 
respectively)
Richards, 201212 - Cancer-specific survival - Kaplan-Meier
- Cox proportional hazards regression
- In univariate analysis, EØ count did not associate with cancer-specific survival (HR 1.72; 95% CI 0.89 - 3.35; p = 0.11)
Nespoli, 200414 - 5-year overall survival - Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- In univariate analysis, EØ infiltration did not associated with survival (p ≥ 0.3)
Nagtegaal, 200115 -Cumulative survival (2-year) 
- Local recurrence rate (2 year)
- Distant metastases rate (2year)
- Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- In univariate analysis, peritumoural EØ directly associated with cumulative survival (p = 0.0008) and inversely associated with local 
recurrence and distant metastases (p = 0.007 and 0.009, respectively)
- In multivariate analysis, peritumoural EØ showed independent prognostic value regarding cumulative survival, additional to TNM 
staging
Fernández-Aceñero, 200016 - Overall survival
- Relapse-free survival
- Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- Higher EØ counts independently associated with longer overall survival and relapse-free survival (p = 0.0005 and p = 0.0009, 
respectively)
Nielsen, 199918 - Overall survival - Kaplan-Meier and log-rank tests
- Cox proportional hazards regression
- EØ count significantly predicted a good overall survival (p < 0.0001), with a progressive effect of increasing counts on the survival 
improvement
- In univariate analysis, EØ count significantly associated with survival (HR 0.74; 95% CI 0.66 - 0.84; p < 0.0001)
- In multivariate analysis, EØ count independently associated with survival (HR 0.81; 95% CI 0.72 - 0.92; p = 0.001)
- EØ counts directly associated with survival in Dukes B and C stages (p = 0.03 and 0.002, respectively)
Fisher, 198920 - Overall survival - Life table plots
- Mantel-Cox statistic
- Overall survival was higher in patients whose tumours had 10 or more EØ
- After adjustment for Dukes’ stage or treatment, the No. of EØ had no prognostic value
Pretlow, 198323 - Survival at 18 months - Wilcoxon 2-sample test
- Fisher’s exact test
- Survival was significantly greater when more than 30 EØ / mm2 were counted (p = 0.028)
TATE: tumour associated tissue eosinophilia; CRC: colorectal cancer; EØ: eosinophil(s); HR: hazard ratio; CI: confidence interval; No(s).: number(s)
Table 4 – Association between TATE and colorectal adenoma-carcinoma progression
First author, year of publication Results p value
Kiziltaᶊ, 200813
Moezzi, 200017
Hyperplastic polyps < Adenomas < 0.001
Kiziltaᶊ, 200813 Hyperplastic polyps < Adenocarcinomas 0.022
Cho, 201610
Kiziltaᶊ, 200813
Moezzi, 200017
Adenomas > Adenocarcinomas < 0.001
Cho, 201610
Kiziltaᶊ, 200813
Low grade dysplasia = High grade dysplasia > 0.05
High grade dysplasia > Adenocarcinomas < 0.001
Moezzi, 200017 Intramucosal carcinoma > Invasive carcinoma < 0.0001
TATE: tumour associated tissue eosinophilia
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namely stromal eosinophils, may prevent CRC progression 
as stated by Prizment et al,9 which is in line with the decrease 
of TATE in adenoma-carcinoma progression of colorectal 
lesions.10,13,17 In conclusion, these results also point to 
TATE as a potential immune-evading strategy of CRC.10 
Therefore, in addition to investigating the mechanisms of 
action of TATE in the context of CRC, it is very important 
to continue research on the power of TATE in the clinical 
management of CRC patients. For example, given the 
decrease of TATE in adenoma-carcinoma progression, 
TATE has been proposed as a marker of risk for the 
development of CRC, as well as an indicator for more and 
tighter surveillance schemes.13,17 Additionally, TATE may 
be used as a diagnostic tool to differentiate hyperplastic 
polyps, adenomatous polyps and serrated adenomas.13,17 
In our review, we only found three articles concerning this 
topic,10,13,17 so, clearly, more research is needed in this area. 
 A major limitation to our review, like in previous 
ones,6,28 was the variability between methodologies used 
in the original research manuscripts which impaired a 
more meaningful interpretation of the results and the 
establishment of a threshold above which TATE could predict 
CRC progression. While the use of immunohistochemistry 
technique strengthens the identification of tissue 
eosinophils, an easy, standardized and cost-effective 
measurement system would be of benefit to enhance 
future research.4,9 Furthermore, immunohistochemistry 
is not free from faults.29 In fact, TATE was assessed in 
hematoxylin-eosin stained sections in the majority of the 
included studies, without compromising the results.10-13,15-18 
Nevertheless, how TATE should be evaluated in terms of 
location and scoring system, remains unclear. Klintrup et al 
developed an easy and highly reproductive score system 
– the Klintrup-Mäkinen score – to assess peritumoural 
overall inflammatory reaction in routinely stained CRC 
specimens, which proved to be an independent favourable 
predictor of survival in CRC patients.44 In that study, higher 
eosinophilic grade at the invasive margin showed a trend 
towards a better prognosis.44 Accordingly, several studies 
in our series highlighted peritumoural location for TATE 
evaluation.11,15,18,20 TATE can be easily evaluated in routinely 
processed tissues and peritumoural / invasive margins 
appear to be the most reliable areas for TATE evaluation. 
Because of all this, TATE seems to meet the standards of a 
good histopathological prognostic marker as established by 
Schneider and Langner.4 
CONCLUSION
 According to published studies, we concluded that: 1) 
current evidence points to TATE as a promising independent 
prognostic marker in CRC; 2) TATE is inversely associated 
with the metastatic behaviour of CRC; 3) TATE decreases 
with adenoma-carcinoma progression of colorectal lesions; 
and 4) TATE evaluation may have implications on the 
surveillance schedule and treatments offered to patients 
diagnosed with CRC. These exciting and promising data 
call for future research on the role of eosinophils in CRC.
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